{'fraction_non_alphanumeric': 0.029914529914529916, 'fraction_numerical': 0.002136752136752137, 'mean_word_length': 5.513888888888889, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Road to identifying endpoint biomarkers in the treatment of nonalcoholic steatohepatitis: are we there yet?

In the United States (US), the landscape of chronic liver disease has been in flux in recent years as chronic hepatitis C virus (HCV) infection is no longer the leading indication for liver transplantation and now ranks behind alcoholic liver disease (ALD) and nonalcoholic steatohepatitis (NASH) as the third leading indication for liver transplantation (1).